Cytokinetics INC Form 4 insider transactions

Cytokinetics' CEO, Robert Blum, exercised stock options and sold a portion of the acquired shares on September 30, 2024.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares on September 17, 2024.

Robert I. Blum, President and CEO of Cytokinetics, exercised stock options and sold shares on September 16, 2024.

Director Lynne Parshall exercised stock options and sold shares of Cytokinetics Inc. on September 9, 2024.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares on September 3, 2024.

Robert Blum, President & CEO of Cytokinetics, reports exercising stock options and selling shares on September 3, 2024.

Brett A. Pletcher, EVP, Chief Legal Officer of Cytokinetics Inc, reports the acquisition of stock options and restricted stock units as an inducement grant.

Director Lynne Parshall exercised stock options and sold shares of Cytokinetics Inc. on August 26, 2024.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reports the acquisition and disposal of Cytokinetics common stock and derivative securities on August 20, 2024.

Robert Blum, President & CEO of Cytokinetics Inc, reported a gift transaction involving 1,956 shares of common stock on August 19, 2024.

Cytokinetics' CEO, Robert Blum, exercised stock options and sold shares on August 12, 2024, according to a Form 4 filing with the SEC.

Director Lynne Parshall exercised stock options and sold shares of Cytokinetics Inc. on August 12, 2024.

EVP of Research & Development at Cytokinetics, Fady Ibraham Malik, exercised stock options and sold shares on August 6th and 7th, 2024.

Director Lynne Parshall exercised stock options and sold shares of Cytokinetics Inc. on July 29, 2024.

Cytokinetics CEO Robert Blum exercised stock options and sold shares on July 30, 2024, according to a Form 4 filing with the SEC.

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, reports the acquisition and disposal of company stock and derivative securities on July 23, 2024.

Director Lynne Parshall reports exercising stock options and selling shares of Cytokinetics on July 15, 2024.

Robert Blum, President & CEO of Cytokinetics, reports the exercise of stock options and sale of common stock on July 10, 2024.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold shares on July 9, 2024.

Director Robert Arthur Harrington of Cytokinetics Inc. (CYTK) sold 253 shares of common stock at a price of $54.61 on July 5, 2024.

Director Nancy Wysenski acquired 114 shares of Cytokinetics Inc. common stock on July 1, 2024, in lieu of a cash retainer payment.

Director Wendell Wierenga acquired 114 shares of Cytokinetics Inc. common stock on July 1, 2024, as a stock award in lieu of a cash retainer payment.

Director Edward M. Kaye acquired 228 shares of Cytokinetics Inc. common stock on July 1, 2024, as a stock award in lieu of a cash retainer payment.

Director John T. Henderson reports acquiring 388 shares of Cytokinetics Inc. common stock in lieu of a cash retainer payment.

Director Robert Arthur Harrington acquired 228 shares of Cytokinetics Inc. common stock on July 1, 2024, as a stock award in lieu of a cash retainer payment.

Director Lynne Parshall exercised stock options and sold shares of Cytokinetics Inc. on July 1, 2024.

Cytokinetics CEO Robert Blum sold 11,500 shares of common stock at $54.05 per share on July 1, 2024, according to a Form 4 filing.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reported the acquisition and disposal of company stock on June 25, 2024.

Director Lynne Parshall exercised stock options and sold shares of Cytokinetics on June 17, 2024.

Cytokinetics CEO Robert Blum sold a portion of his common stock holdings on June 17, 2024.